Literature DB >> 20957467

The attitude of oncology physicians and nurses to the acceptance of new drugs for gene therapy.

Zi-ming Liu1, Chang Liu, Jun-ying Li, Chun-hua Yu, Yu Jiang.   

Abstract

With the efficacy of gene therapy verified in phase III trials, cancer patients will consider whether to accept gene therapy sooner or later. The purpose of this study is to investigate the attitudes of oncology physicians and nurses regarding effective gene therapy. A questionnaire was administered to 368 oncology physicians and nurses. A total of 328 valid questionnaires were returned (response rate, 89.1%). Gene therapy was considered as very safe or safe by 256 (78.0%) participants. Regardless of the stage of cancer, participants who advised patients to enroll in clinical trials and considered gene therapy as safe tended to accept the effective gene therapy. Gene therapy is considered to be a safe treatment. Most participants are willing to accept effective and verified gene therapy on the assumption that they themselves suffer from cancers.

Entities:  

Mesh:

Year:  2011        PMID: 20957467     DOI: 10.1007/s13187-010-0172-0

Source DB:  PubMed          Journal:  J Cancer Educ        ISSN: 0885-8195            Impact factor:   2.037


  25 in total

1.  Gene therapy and the public: a matter of trust.

Authors:  H Gottweis
Journal:  Gene Ther       Date:  2002-06       Impact factor: 5.250

2.  To tell or not to tell: attitudes of Chinese oncology nurses towards truth telling of cancer diagnosis.

Authors:  Jun-Ying Li; Chang Liu; Li-Qun Zou; Mei-Juan Huang; Chun-Hua Yu; Gui-Ying You; Yong-Dong Jiang; Hong Li; Yu Jiang
Journal:  J Clin Nurs       Date:  2008-06-28       Impact factor: 3.036

3.  Cancer gene therapy steadily advances.

Authors:  Vicki Brower
Journal:  J Natl Cancer Inst       Date:  2008-09-09       Impact factor: 13.506

4.  Combined effects of soluble vascular endothelial growth factor receptor FLT-1 gene therapy and cisplatin chemotherapy in human tongue carcinoma xenografts.

Authors:  Zhen-Nan Gao; Yu-Quan Wei; Pi-Shan Yang; Xin Xu; Hua-Qiang Zhao; Xin Huan; Bing Kang
Journal:  Oral Oncol       Date:  2006-09-25       Impact factor: 5.337

5.  Acceptance of gene therapy by the heart surgery patient.

Authors:  Johannes Bonatti; Christa Haeusler; Alexander Klaus; Monika Fink; Angelika Hammerer-Lercher; Günther Laufer
Journal:  Eur J Cardiothorac Surg       Date:  2002-06       Impact factor: 4.191

6.  Targeting metastatic cancer from the inside: a new generation of targeted gene delivery vectors enables personalized cancer vaccination in situ.

Authors:  Erlinda M Gordon; John P Levy; Rebecca A Reed; W Nina Petchpud; Liqiong Liu; Carlan B Wendler; Frederick L Hall
Journal:  Int J Oncol       Date:  2008-10       Impact factor: 5.650

7.  Adenovirus-mediated ING4 expression suppresses lung carcinoma cell growth via induction of cell cycle alteration and apoptosis and inhibition of tumor invasion and angiogenesis.

Authors:  Yufeng Xie; Haifeng Zhang; Weihua Sheng; Jim Xiang; Zhenmin Ye; Jicheng Yang
Journal:  Cancer Lett       Date:  2008-09-11       Impact factor: 8.679

8.  Different attitudes of Chinese patients and their families toward truth telling of different stages of cancer.

Authors:  Yu Jiang; Chang Liu; Jun-Ying Li; Mei-Juan Huang; Wen-Xiu Yao; Ru Zhang; Bing Yao; Xiao-Bo Du; Jing Chen; Ke Xie; Xia Zhao; Yu-Quan Wei
Journal:  Psychooncology       Date:  2007-10       Impact factor: 3.894

9.  Eight-year safety follow-up of coronary artery disease patients after local intracoronary VEGF gene transfer.

Authors:  M Hedman; K Muona; A Hedman; A Kivelä; M Syvänne; J Eränen; A Rantala; J Stjernvall; M S Nieminen; J Hartikainen; S Ylä-Herttuala
Journal:  Gene Ther       Date:  2009-02-12       Impact factor: 5.250

10.  Points to consider for ethics committees in human gene therapy trials.

Authors:  U Dettweiler; P Simon
Journal:  Bioethics       Date:  2001-10       Impact factor: 1.898

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.